Safety related drug-labelling changes

被引:36
作者
Hauben, M
Reich, L
机构
[1] Pfizer Inc, Risk Management Strategy, New York, NY 10017 USA
[2] NYU, Sch Med, Dept Med, New York, NY USA
[3] New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA
[4] New York Med Coll, Dept Community & Prevent Med, Valhalla, NY 10595 USA
关键词
D O I
10.2165/00002018-200427100-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: With increasing volumes of postmarketing safety surveillance data, data mining algorithms (DMAs) have been developed to search large spontaneous reporting system (SRS) databases for disproportional statistical dependencies between drugs and events. A crucial question is the proper deployment of such techniques within the universe of methods historically used for signal detection. One question of interest is comparative performance of algorithms based on simple forms of disproportionality analysis versus those incorporating Bayesian modelling. A potential benefit of Bayesian methods is a reduced volume of signals, including false-positive signals. Objective: To compare performance of two well described DMAs (proportional reporting ratios [PRRs] and an empirical Bayesian algorithm known as multi-item gamma Poisson shrinker [MGPS]) using commonly recommended thresholds on a diverse data set of adverse events that triggered drug labelling changes. Methods: PRRs and MGPS were retrospectively applied to a diverse sample of drug-event combinations (DECs) identified on a government Internet site for a 7-month period. Metrics for this comparative analysis included the number and proportion of these DECs that generated signals of disproportionate reporting with PRRs, MGPS, both or neither method, differential timing of signal generation between the two methods, and clinical nature of events that generated signals with only one, both or neither method. Results: There were 136 relevant DECs that triggered safety-related labelling changes for 39 drugs during a 7-month period. PRRs generated a signal of disproportionate reporting with almost twice As many DECs as MGPS (77 vs 40). No DECs were flagged by MGPS only. PRRs highlighted DECs in advance of MGPS (1-15 years) and a label change (1-30 years). For 59 DECs, there was no signal with either DMA. DECs generating signals of disproportionate reporting with only PRRs were both medically serious and non-serious. Discussion/conclusion: In most instances in which a DEC generated a signal of disproportionate reporting with both DMAs (almost twice as many with PRRs), the signal was generated using PRRs in advance of MGPS. No medically important events were signalled only by MGPS. It is likely that the incremental utility of DMAs are highly situation-dependent. It is clear, however, that the volume of signals generated by itself is an inadequate criterion for comparison and that clinical nature of signalled events and differential timing of signals needs to be considered. Accepting commonly recommended threshold criteria for DMAs examined in this study as universal benchmarks for signal detection is not justified.
引用
收藏
页码:735 / 744
页数:10
相关论文
共 17 条
  • [1] A Bayesian neural network method for adverse drug reaction signal generation
    Bate, A
    Lindquist, M
    Edwards, IR
    Olsson, S
    Orre, R
    Lansner, A
    De Freitas, RM
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 315 - 321
  • [2] *CTR DRUG EV RES, DRUG INF ADV EV REP
  • [3] DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
  • [4] Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
    Evans, SJW
    Waller, PC
    Davis, S
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) : 483 - 486
  • [5] Practical pharmacovigilance analysis strategies
    Gould, AL
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2003, 12 (07) : 559 - 574
  • [6] Trimethoprim-induced hyperkalaemia - lessons in data mining
    Hauben, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (03) : 338 - 339
  • [7] A brief primer on automated signal detection
    Hauben, M
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 1117 - 1123
  • [8] HAUBEN M, IN PRESS BR J CLIN P
  • [9] KENNEDY DL, 2000, PHARMACOEPIDEM DR S, P151
  • [10] A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO International Database
    Lindquist, M
    Ståhl, M
    Bate, A
    Edwards, IR
    Meyboom, RHB
    [J]. DRUG SAFETY, 2000, 23 (06) : 533 - 542